{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:56:28Z","timestamp":1791284188111,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with lichen planus (LP) refractory to available therapies often experience a high disease burden, representing a population with a clear unmet need for new treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of secukinumab 300\u2005mg over 32 weeks in adult patients with biopsy-proven cutaneous LP (CLP), mucosal LP (MLP) or lichen planopilaris (LPP) that is inadequately controlled by topical corticosteroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PRELUDE was a randomized double-blind placebo-controlled phase II proof-of-concept study that enrolled patients with CLP, MLP or LPP. Eligible patients were randomized to either secukinumab 300\u2005mg every 4 weeks for 32 weeks (SECQ4W) or placebo for 16 weeks followed by secukinumab 300\u2005mg every 2 weeks (SECQ2W) for 16 weeks. The primary endpoint was achievement of the newly designed Investigator\u2019s Global Assessment (IGA) score \u2264 2 at week 16.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 111 patients were randomized (n = 37 each) to CLP, MLP and LPP cohorts. As the proof-of-concept criteria were not met for any of the three cohorts, the primary objective was not met. A numerically higher proportion of patients achieved IGA \u2264 2 response at week 16 with SECQ4W vs. placebo in the MLP {37.5% [95% credibility interval (Crl) 20.3\u201357.2] vs. 23.1% (95% Crl 6.5\u201349.2)} and LPP cohorts [37.5% (95% Crl 20.2\u201357.3) vs. 30.8% (95% Crl 10.8\u201357.6)]. In the LPP cohort, a sustained response for IGA \u2264 2 from week 16 to week 32 was achieved with SECQ4W (week 16, 37.5%; week 32, 45.8%), and a substantial improvement was observed in IGA \u2264 2 response in patients from this cohort who switched from placebo (week 16, 30.8%) to SECQ2W after week 16 (week 32, 63.6%). The safety profile was consistent with the known profile of secukinumab and showed no new or unexpected signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PRELUDE is the first randomized controlled basket trial evaluating interleukin (IL)-17A inhibition with secukinumab across three subtypes of LP. Secukinumab was well tolerated and safe, showing different response rates across the three subtypes, with numerical IGA improvements in MLP and LPP, and no response in CLP. The study raises the question of a differential role of IL-17A across LP subtypes. The novel IGA score showed significant correlation with both patient- and physician-reported outcome measurements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae181","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:39:47Z","timestamp":1715243987000},"page":"680-690","source":"Crossref","is-referenced-by-count":19,"title":["Secukinumab in adult patients with lichen planus: efficacy\u00a0and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study"],"prefix":"10.1093","volume":"191","author":[{"given":"Thierry","family":"Passeron","sequence":"first","affiliation":[{"name":"University C\u00f4te d\u2019Azur, CHU Nice, Department of Dermatology , Nice ,","place":["France"]},{"name":"University C\u00f4te d\u2019Azur , INSERM U1065, C3M, Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"Novartis Pharma , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ehst","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weiss","sequence":"additional","affiliation":[{"name":"Georgia Dermatology Partners , Snellville, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Sluzevich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic , Jacksonville, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[{"name":"Hautklinik, Friedrich-Alexander-University of Erlangen-N\u00fcrnberg (FAU) Department of Dermatology, University Hospital Erlangen , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Reygagne","sequence":"additional","affiliation":[{"name":"Sabouraud Centre, St Louis Hospital , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Wohlrab","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg , Halle (Saale) ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[{"name":"Newport Dermatology & Laser Associates , Newport Beach, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"Fazel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California at Davis School of Medicine , Sacramento, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Muscianisi","sequence":"additional","affiliation":[{"name":"Novartis Gene Therapies , Bannockburn, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Fan","sequence":"additional","affiliation":[{"name":"Novartis Pharma Shanghai , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Hampele","sequence":"additional","affiliation":[{"name":"Novartis Pharma , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Compagno","sequence":"additional","affiliation":[{"name":"Novartis Pharma , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"2024102112265178100_ljae181-B1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1365-4632.2009.04062.x","article-title":"Lichen planus","volume":"48","author":"Lehman","year":"2009","journal-title":"Int J Dermatol"},{"key":"2024102112265178100_ljae181-B2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMcp1103641","article-title":"Lichen planus","volume":"366","author":"Le Cleach","year":"2012","journal-title":"N Engl J Med"},{"key":"2024102112265178100_ljae181-B3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/odi.13323","article-title":"Worldwide prevalence of oral lichen planus: a systematic review and meta-analysis","volume":"27","author":"Gonz\u00e1lez-Moles","year":"2021","journal-title":"Oral Dis"},{"key":"2024102112265178100_ljae181-B4","first-page":"309","article-title":"Clinical variants of lichen planus","volume":"11","author":"Wagner","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024102112265178100_ljae181-B5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000196973","article-title":"Quality of life and psychological problems of patients with oral mucosal disease in dermatological practice","volume":"218","author":"Tabolli","year":"2009","journal-title":"Dermatology"},{"key":"2024102112265178100_ljae181-B6","first-page":"1","article-title":"Characterization of mononuclear cells of inflammatory infiltrates in oral tissues. A histochemical and immunohistochemical study of labial salivary glands in Sj\u00f6gren\u2019s syndrome and of oral lesions in systemic lupus erythematosus and in lichen planus","volume":"84","author":"Kilpi","year":"1988","journal-title":"Proc Finn Dent Soc"},{"key":"2024102112265178100_ljae181-B7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.1984.tb06629.x","article-title":"Oral lichen planus: an immunoperoxidase study using monoclonal antibodies to lymphocyte subsets","volume":"111","author":"Matthews","year":"1984","journal-title":"Br J Dermatol"},{"key":"2024102112265178100_ljae181-B8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2230.2005.01866.x","article-title":"Erosive lichen planus of the vulva: weak circulating basement membrane zone antibodies are present","volume":"30","author":"Cooper","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"2024102112265178100_ljae181-B9","first-page":"136","article-title":"Comparison of serum autoantibodies to desmogleins I, III in patients with oral lichen planus and healthy controls","volume":"10","author":"Gholizadeh","year":"2015","journal-title":"Iran J Pathol"},{"key":"2024102112265178100_ljae181-B10","first-page":"91","article-title":"Serum level of interleukin 17 in patients with erosive and non erosive oral lichen planus","volume":"7","author":"Pouralibaba","year":"2013","journal-title":"J Dent Res Dent Clin Dent Prospects"},{"key":"2024102112265178100_ljae181-B11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/j.1365-2133.2011.10793.x","article-title":"Possible role of interleukin-17 in the pathogenesis of lichen planus","volume":"166","author":"Shaker","year":"2012","journal-title":"Br J Dermatol"},{"key":"2024102112265178100_ljae181-B12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaci.2018.02.044","article-title":"TH1\/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus","volume":"142","author":"Schmidt","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024102112265178100_ljae181-B13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/odi.12718","article-title":"IL17A polymorphism and elevated IL17A serum levels are associated with oral lichen planus","volume":"24","author":"Gueiros","year":"2018","journal-title":"Oral Dis"},{"key":"2024102112265178100_ljae181-B14","doi-asserted-by":"crossref","first-page":"1203776","DOI":"10.3389\/fimmu.2023.1203776","article-title":"Skin-infiltrating T cells display distinct inflammatory signatures in lichen planus, bullous pemphigoid and pemphigus vulgaris","volume":"14","author":"Schinner","year":"2023","journal-title":"Front Immunol"},{"key":"2024102112265178100_ljae181-B15","doi-asserted-by":"crossref","first-page":"6521274","DOI":"10.1155\/2020\/6521274","article-title":"Increased serum level and high tissue immunoexpression of interleukin 17 in cutaneous lichen planus: a novel therapeutic target for recalcitrant cases?","volume":"2020","author":"\u017bychowska","year":"2020","journal-title":"Dis Markers"},{"key":"2024102112265178100_ljae181-B16","doi-asserted-by":"crossref","first-page":"eabl9165","DOI":"10.1126\/sciimmunol.abl9165","article-title":"Classification of human chronic inflammatory skin disease based on single-cell immune profiling","volume":"7","author":"Liu","year":"2022","journal-title":"Sci Immunol"},{"key":"2024102112265178100_ljae181-B17","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3389\/fimmu.2019.01808","article-title":"Therapeutic targeting of Th17\/Tc17 cells leads to clinical improvement of lichen planus","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"2024102112265178100_ljae181-B18","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1111\/jdv.17068","article-title":"Successful treatment of recalcitrant genital lichen planus with secukinumab","volume":"35","author":"Rezzag-Mahcene","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102112265178100_ljae181-B19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jdv.16124","article-title":"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease","volume":"34","author":"Reich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102112265178100_ljae181-B20","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-\u00adsevere plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2024102112265178100_ljae181-B21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in \u00admoderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2024102112265178100_ljae181-B22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3121\/cmr.2023.1822","article-title":"A systematic review of interleukin-17 in oral lichen planus: from etiopathogenesis to treatment","volume":"21","author":"Agha-Hosseini","year":"2023","journal-title":"Clin Med Res"},{"key":"2024102112265178100_ljae181-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jop.12142","article-title":"Inflammation-related cytokines in oral lichen planus: an overview","volume":"44","author":"Lu","year":"2015","journal-title":"J Oral Pathol Med"},{"key":"2024102112265178100_ljae181-B24","doi-asserted-by":"crossref","first-page":"1203776","DOI":"10.3389\/fimmu.2023.1203776","article-title":"Skin-infiltrating T cells display distinct inflammatory signatures in lichen planus, bullous pemphigoid and pemphigus vulgaris","volume":"14","author":"Schinner","year":"2023","journal-title":"Front Immunol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae181\/58360015\/ljae181.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/5\/680\/59927353\/ljae181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/5\/680\/59927353\/ljae181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T08:27:54Z","timestamp":1729499274000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/5\/680\/7670732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,13]]},"published-print":{"date-parts":[[2024,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae181","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,5,13]]}}}